SEC Form 4 · accession 0001177648-18-000035

ENANTA PHARMACEUTICALS INC · ENTA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Sr. VP & Chief Medical Officer

Period of report

Sep 20, 2018

Accepted (ET)

Sep 21, 2018 · 4:18 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001177648

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Sep 20, 2018	M	2,955	$43.46	A	4,155	D
Common Stock^F2	Sep 20, 2018	S	500	$93.0182	D	3,655	D
Common Stock^F3	Sep 20, 2018	S	453	$93.8965	D	3,202	D
Common Stock^F4	Sep 20, 2018	S	1,229	$94.7529	D	1,973	D
Common Stock^F5	Sep 20, 2018	S	602	$95.8449	D	1,371	D
Common Stock^F6	Sep 20, 2018	S	1,371	$96.8942	D	0	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F7	$43.46	Sep 20, 2018	M	2,955	D	—	Jun 29, 2025	Common Stock	2,955	72,270	D

F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2018.
F2The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $92.87 to $93.08, inclusive.
F3The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $93.34 to $94.11, inclusive.
F4The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $94.35 to $95.12, inclusive.
F5The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $95.76 to $96.26, inclusive.
F6The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $96.46 to $97.29, inclusive.
F7The option, representing a right to purchase a total of 90,000 shares, became or will become exercisable as follows: twenty-five percent (25%) of the shares subject to such option became exercisable on June 29, 2016 (the "Anniversary Date") and the remainder became or will become exercisable quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over three years after the Anniversary Date.